Gamida Cell, a Jerusalem, Israel-based developer of cellular and immune therapies for the treatment of cancer and orphan genetic diseases, received a grant of up to $4.4m.
The Israel Innovation Authority (formerly the Office of the Chief Scientist) of the Israeli Ministry of Economy and Industry provided the award.
The non-dilutive funding will support Gamida Cell’s ongoing research and development efforts including its Phase 3 registration study of NiCord® for hematological malignancies (blood cancers like leukemia and lymphoma), and its clinical trials of CordIn® for sickle cell disease and thalassemia and NK cells as a potential immune therapy for cancer.
Led by Dr. Yael Margolin, president and CEO, Gamida Cell is a world leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases.
The company’s pipeline of products are in development to treat a wide range of conditions including cancer, genetic hematological diseases such as sickle cell disease and thalassemia, bone marrow failure syndromes such as aplastic anemia, genetic metabolic diseases and refractory autoimmune diseases.
Current shareholders in the company include Novartis, Elbit Imaging, Clal Biotechnology Industries, Israel Healthcare Venture, Teva Pharmaceutical Industries, Denali Ventures and Auriga Ventures.